Literature DB >> 23986339

Invasive bladder cancer: ignoring the data.

Derek Raghavan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23986339      PMCID： PMC3755924          DOI： 10.1634/theoncologist.2013-0281

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  22 in total

1.  Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder.

Authors:  D M Wallace; D Raghavan; K A Kelly; T F Sandeman; I G Conn; N Teriana; J Dunn; J Boulas; T Latief
Journal:  Br J Urol       Date:  1991-06

Review 2.  Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.

Authors:  David D Chism; Michael E Woods; Matthew I Milowsky
Journal:  Oncologist       Date:  2013-07-24

3.  Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.

Authors:  H I Scher; A Yagoda; H W Herr; C N Sternberg; G Bosl; M J Morse; P C Sogani; R C Watson; D D Dershaw; V Reuter
Journal:  J Urol       Date:  1988-03       Impact factor: 7.450

4.  Intravenous cis-platinum for invasive bladder cancer. Safety and feasibility of a new approach.

Authors:  D Raghavan; B Pearson; G Coorey; W Woods; D Arnold; J Smith; J Donovan; P Langdon
Journal:  Med J Aust       Date:  1984-03-03       Impact factor: 7.738

5.  Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study.

Authors:  M Stöckle; W Meyenburg; S Wellek; G Voges; U Gertenbach; J W Thüroff; C Huber; R Hohenfellner
Journal:  J Urol       Date:  1992-08       Impact factor: 7.450

6.  Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer.

Authors:  Michael P Porter; Matthew C Kerrigan; Bonnie M K Donato; Scott D Ramsey
Journal:  Urol Oncol       Date:  2009-05-17       Impact factor: 3.498

7.  Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.

Authors:  P K Schultz; H W Herr; Z F Zhang; D F Bajorin; A Seidman; A Sarkis; W R Fair; D Scherr; G J Bosl; H I Scher
Journal:  J Clin Oncol       Date:  1994-07       Impact factor: 44.544

8.  Initial intravenous cis-platinum therapy: improved management for invasive high risk bladder cancer?

Authors:  D Raghavan; B Pearson; P Duval; J Rogers; M Meagher; R Wines; H Mameghan; J Boulas; D Green
Journal:  J Urol       Date:  1985-03       Impact factor: 7.450

9.  The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial.

Authors:  D G Skinner; J R Daniels; C A Russell; G Lieskovsky; S D Boyd; P Nichols; W Kern; J Sakamoto; M Krailo; S Groshen
Journal:  J Urol       Date:  1991-03       Impact factor: 7.450

Review 10.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.

Authors: 
Journal:  Lancet       Date:  2003-06-07       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.